Quantcast
Home > Quotes > RGNX

REGENXBIO Inc. Common Stock (RGNX) Quote & Summary Data

RGNX 
$64.66
*  
2.28
3.66%
Get RGNX Alerts
*Delayed - data as of Nov. 16, 2018  -  Find a broker to begin trading RGNX now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
88.5
Today's High / Low
$ 65.34 / $ 61.1089
Share Volume
417,744
50 Day Avg. Daily Volume
502,994
Previous Close
$ 62.38
52 Week High / Low
$ 85.10 / $ 23.25
Market Cap
2,317,437,613
P/E Ratio
28.48
Forward P/E (1y)
28.88
Earnings Per Share (EPS)
$ 2.27
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
2.69

Intraday Chart

Shares Traded

Share Volume:
417,744
50 Day Avg. Daily Volume:
502,994

P/E Ratio

P/E Ratio:
28.48
Forward P/E (1y):
28.88
Earnings Per Share (EPS):
$ 2.27

Trading Range

The current last sale of $64.66 is 178.11% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 65.34 $ 85.10
 Low: $ 61.1089 $ 23.25

Company Description (as filed with the SEC)

We are a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Our gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Through a single administration, our gene therapy product candidates are designed to provide long-lasting effects, potentially significantly altering the course of disease and delivering improved patient outcomes. Our product candidate RGX-314 is for the treatment of wet age-related macular degeneration (wet AMD), a leading cause of total and partial vision loss in the United States, Europe and Japan. We began enrollment in the Phase I clinical trial for RGX-314 for the treatment of wet AMD in May 2017 and have completed dosing of three cohorts of six patients each, a total of 18 patients, in the Phase I clinical trial.  ... More ...  


Risk Grade

Where does RGNX fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 61.96
Open Date:
Nov. 16, 2018
Close Price:
$ 62.38
Close Date:
Nov. 16, 2018

Consensus Recommendation

Analyst Info



Another Bailout?? Why is the SEC boosting big banks and HFT's bottom lines?
x